Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31470851 | 1.00 | CA12 (0.46) | CA12CA1CA2CA9CRBN | |
| SCHEMBL31470850 | 1.00 | CA12 (0.46) | CA12CA1CA2CA9CRBN | |
| SCHEMBL22371802 | 0.81 | CA12 (0.50) | CA12CA1CA2CA9 | |
| SCHEMBL14428362 | 0.81 | CA12 (0.50) | CA12CA1CA2CA9 | |
| SCHEMBL22371820 | 0.81 | CA12 (0.50) | CA12CA1CA2CA9 | |
| SCHEMBL5453227 | 0.81 | CA12 (0.53) | CA12CA1CA2CA9 | |
| SCHEMBL14428359 | 0.80 | IDO1 (0.33) | CRBN | |
| SCHEMBL22371805 | 0.77 | CA12 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL6370201 | 0.72 | CA12 (0.56) | CA12CA1CA2CA9 | |
| SCHEMBL5455649 | 0.70 | CA12 (0.45) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600742-B2 | Markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy | WWIKY BIOSCIENCES INC. (CA) | 2026-04-14 | — | — | US | disclosed |
| US-20200276338-A1 | BIOREDUCTIVELY-ACTIVATED COMPOUNDS, THEIR PRODRUGS, RADIOPHARMACEUTICALS, THE COMPOSITIONS, AND THEIR APPLICATIONS IN MULTIMODAL THERANOSTIC MANAGEMENT OF HYPOXIA DISEASES INCLUDING CANCER | WWIKY BIOSCIENCES INC. (CA) | 2020-09-03 | — | — | US | disclosed |
| US-20200216486-A1 | MARKERS, CONJUGATES, COMPOSITIONS AND METHODS FOR HYPOXIA IMAGING, MAPPING, AND THERAPY | WWIKY BIOSCIENCES INC. (CA) | 2020-07-09 | — | — | US | disclosed |
| CN-111356698-A | Markers, conjugates, compositions and methods for hypoxia imaging, mapping and therapy | 阿尔伯塔大学理事会 | 2020-06-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276338-A1 | BIOREDUCTIVELY-ACTIVATED COMPOUNDS, THEIR PRODRUGS, RADIOPHARMACEUTICALS, THE COMPOSITIONS, AND THEIR APPLICATIONS IN MULTIMODAL THERANOSTIC MANAGEMENT OF HYPOXIA DISEASES INCLUDING CANCER | HIF1A, HIF1AN, PAICS | CA12 17/4885CA1 50/4885CA2 43/4885 |
| US-20200216486-A1 | MARKERS, CONJUGATES, COMPOSITIONS AND METHODS FOR HYPOXIA IMAGING, MAPPING, AND THERAPY | HYOU1, HIF1A, HIF1AN | CA12 33/4885CA1 38/4885CA2 102/4885 |
| US-12600742-B2 | Markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy | HIF1A, HIF1AN, HYOU1 | CA12 23/4885CA1 45/4885CA2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.